Page last updated: 2024-10-22

anastrozole and Menopause

anastrozole has been researched along with Menopause in 16 studies

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research Excerpts

ExcerptRelevanceReference
"In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis."9.11The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004)
"This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i."7.79Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013)
"Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms."6.71Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004)
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years."6.42Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003)
"In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis."5.11The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004)
"Androstenedione, the main circulating ovarian hormone present after menopause, has been shown to positively correlate with poor spatial memory in an ovary-intact rodent model of follicular depletion, and to impair spatial memory when administered exogenously to surgically menopausal ovariectomized rats."3.81Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats. ( Acosta, JI; Alderete, TJ; Bimonte-Nelson, HA; Camp, BW; Demers, LM; Koebele, SV; Mennenga, SE; Mousa, AA; Tsang, CW, 2015)
"This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i."3.79Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013)
"Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2."3.71Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001)
"Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms."2.71Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004)
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years."2.42Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003)
"Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns."1.30Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. ( Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK, 1999)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's9 (56.25)29.6817
2010's5 (31.25)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Salmon, RJ1
Glaser, RL1
Dimitrakakis, C1
Mennenga, SE1
Koebele, SV1
Mousa, AA1
Alderete, TJ1
Tsang, CW1
Acosta, JI1
Camp, BW1
Demers, LM1
Bimonte-Nelson, HA1
Goodwin, PJ1
Pritchard, KI1
Kanematsu, M1
Morimoto, M1
Honda, J1
Nagao, T1
Nakagawa, M1
Takahashi, M1
Tangoku, A1
Sasa, M1
Koloszar, S1
Pal, Z1
Kereszturi, A1
Vajda, G1
Pal, A1
Daru, J1
Carlson, RW1
Henderson, IC1
Soysal, S1
Soysal, ME1
Ozer, S1
Gul, N1
Gezgin, T1
Kammerer, S1
Morales, L1
Neven, P1
Timmerman, D1
Christiaens, MR1
Vergote, I1
Van Limbergen, E1
Carbonez, A1
Van Huffel, S1
Ameye, L1
Paridaens, R1
de Cremoux, P1
Diéras, V1
Poupon, MF1
Magdelénat, H1
Sigal-Zafrani, B1
Fourquet, A1
Pierga, JY1
Spano, JP1
Khayat, D1
Delozier, T1
Goss, PE1
Hadji, P1
Subar, M1
Abreu, P1
Thomsen, T1
Banke-Bochita, J1
Fallowfield, LJ1
Leaity, SK1
Howell, A1
Benson, S1
Cella, D1
Miller, WR1
Dixon, JM1
Cameron, DA1
Anderson, TJ1
Baum, M1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Personalised Electronic Record Supported Two-Stage Observational Study of Sleep in Patients With Breast Cancer[NCT05093426]226 participants (Actual)Observational2022-01-15Completed
Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)[NCT02186015]Phase 243 participants (Actual)Interventional2015-02-28Completed
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665]71 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Fatigue

Assessment of fatigue using the Piper Fatigue Scale at weeks 0 and 8. The Piper Fatigue Scale is the average of 22 numeric items, with higher scores indicating greater fatigue [range of scores: 0-10]. Change is calculated as the fatigue score at 8 weeks minus fatigue score at 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionunits on a scale (Median)
Cholecalciferol-0.5

Change in Functional Assessment of Cancer Therapy-breast

"Assessment of quality of life using the functional assessment of cancer therapy-breast symptoms at weeks 0 and 8. Scores range from 0-40 with higher scores indicating better quality of life.~Change was calculated as week 8 score minus week 0 score. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time." (NCT02186015)
Timeframe: 0, 8 weeks

Interventionscore on a scale (Median)
Cholecalciferol0

Change in Functional Assessment of Cancer Therapy-endocrine

Assessment of quality of life using the functional assessment of cancer therapy- endocrine symptoms at weeks 0 and 8. Scores range from 0-76 with higher scores indicating better quality of life. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionscore on a scale (Median)
Cholecalciferol9

Change in Mood

Assessment of mood using the Patient Health Questionnaire 8 (PHQ-8) at weeks 0 and 8. The PHQ-8 ranges from 0-24 with higher scores indicating more distress. Change was assessed as PHQ-8 score at 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionscore on a scale (Median)
Cholecalciferol-1

Change in Muscle Function

Assessment of muscle function using a hand dynamometer at weeks 0 and 8. Change in dominant handgrip strength in kilograms was calculated as 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionkilograms (Median)
Cholecalciferol-0.2

Change in Serum 25(OH)D

Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionng/ml (Median)
Cholecalciferol32

Change in Sleep Quality Assessment

Assessment of sleep using the Pittsburgh Sleep Quality Index (PSQI) at weeks 0 and 8. Scores range from 0-21 with higher scores indicating poorer sleep quality. Change was calculated as week 8 minus week 0 PSQI. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionscore on a scale (Median)
Cholecalciferol-1

Change in Worst Pain Rating From the Beck Pain Scale

Assessment of pain using the Beck Pain Scale at weeks 0 and 8. This is a Likert scale item where a score of 0 corresponds to no pain and a score of 10 corresponds to worst pain. Change is calculated as the worst pain rating at 8 weeks minus the worst pain rating at 0 weeks.Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks

Interventionscore on a scale (Median)
Cholecalciferol0

Reviews

4 reviews available for anastrozole and Menopause

ArticleYear
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis

2003
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    Bulletin du cancer, 2004, Volume: 91, Issue:12

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms

2004
[Aromatase inhibitors in adjuvant setting in breast cancer].
    Bulletin du cancer, 2004, Dec-01, Volume: 91 Suppl 4

    Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne

2004
A vision for the future?
    British journal of cancer, 2001, Volume: 85 Suppl 2

    Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitrile

2001

Trials

3 trials available for anastrozole and Menopause

ArticleYear
The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.
    Human reproduction (Oxford, England), 2004, Volume: 19, Issue:1

    Topics: Adult; Anastrozole; Aromatase Inhibitors; Bone Density; Drug Administration Schedule; Drug Therapy,

2004
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
    Anti-cancer drugs, 2004, Volume: 15, Issue:8

    Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation,

2004
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Breast cancer research : BCR, 2007, Volume: 9, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers

2007

Other Studies

9 other studies available for anastrozole and Menopause

ArticleYear
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
    Bulletin du cancer, 2023, Volume: 110, Issue:10

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy,

2023
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
    Maturitas, 2013, Volume: 76, Issue:4

    Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Fema

2013
Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats.
    Steroids, 2015, Volume: 99, Issue:Pt A

    Topics: Anastrozole; Androgen Antagonists; Androstenedione; Animals; Aromatase Inhibitors; Brain; Cognition

2015
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-20, Volume: 28, Issue:21

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag

2010
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.
    BMC cancer, 2011, Oct-10, Volume: 11

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Female;

2011
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
    Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:1

    Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Atrophy; Endometrial Hyperplasia; End

2012
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
    MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50

    Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C

2003
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Breast cancer research and treatment, 1999, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem

1999
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Breast cancer research and treatment, 1999, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem

1999
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Breast cancer research and treatment, 1999, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem

1999
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Breast cancer research and treatment, 1999, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem

1999
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
    The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr

2001